News | February 06, 2008

Trial Transplants Stem Cells to Prevent Leg Amputations

February 7, 2008 - A Northwestern University Feinberg School of Medicine researcher has launched the first U.S. trial in which a purified form of subjects' own adult stem cells is transplanted into their leg muscles with severely blocked arteries to try to grow new small blood vessels and restore circulation in their legs.

The first two subjects in the 20-site national trial recently underwent the stem cell transplant process at Northwestern Memorial Hospital.

Severely blocked arteries in the leg and sharply diminished blood flow can result in wounds that don't heal, the breakdown of tissue and gangrene. This painful condition, called critical limb ischemia (CLI), results in the amputation of more than 100,000 limbs every year in the United States. It's a serious, emerging health problem that affects 1.4 million people. An estimated 15 percent of the population will have this disease by the time they reach age 70.

The Northwestern-led Phase I/IIa study—which will include 75 people with CLI around the country—targets patients who have exhausted all other medical options including angioplasty, stents and bypass surgery to repair blocked circulation in their legs.

"They're at the end of the therapeutic road and they're ultimately facing potential amputation," said Douglas W. Losordo, M.D., the Eileen M. Foell Professor of Heart Research at the Feinberg School and principal national investigator for the study. "This is hopefully a way to help them avoid that."

Dr. Losordo is director of the university's Feinberg Cardiovascular Research Institute and director of cardiovascular regenerative medicine at Northwestern Memorial Hospital.

"The stem cells themselves can assemble into blood vessels," Dr. Losordo said. "They can also secrete growth factors that stimulate and recruit other stem cells to come into the tissue and help with the repair. It's an amazing biology we're trying to leverage in these folks."

He said preclinical studies transplanting stem cells into the limbs have shown this approach to be effective in mice and rats. "Based on that, we think it has a good chance of helping humans," Dr. Losordo noted.

"This is a dreadful disease in which the profession has failed to offer much in the way of relief for these patients," Dr. Losordo said. "We're hoping this will have some impact."

CLI is the result of advanced peripheral artery disease, which affects about 10 million people in the United States. In peripheral artery disease, people develop blockages in their arteries and vessels that slow or stop the blood flow to their legs. When they have pain at rest in their lower legs and wounds on their legs or feet that will not heal, they have CLI. If left untreated, CLI can result in a patient having toes, a foot, or even a leg amputated.

As CLI progresses, people begin to experience pain when they walk, then when just sitting. The worst pain occurs at night because blood flow is decreased when people lie down. Some have to sleep in chairs to aid the blood flow and lessen the pain.

"Peripheral artery disease is a big health problem," Dr. Losordo said. "An awareness of the impact of this disease on public health is emerging."

High blood pressure, high cholesterol, smoking, and diabetes all raise the risk of having the condition. But some people don't smoke, have diabetes or high blood pressure, and can still have blocked arteries in their legs, Dr. Losordo said.

For the randomized, double blind, placebo-controlled trial, Dr. Losordo uses the subject's own purified stem cells. The subject first takes a drug for five days to stimulate the release of his or her stem cells, called CD34 cells, from bone marrow. An intravenous line is then inserted into a subject's vein to collect blood through a machine that removes a population of blood cells that contains the CD34 stem cells. Dr. Losordo further selects and enriches the cells to select only CD34 cells.

Dr. Losordo's study is supported by Baxter Healthcare Corporation, which manufactures the Isolex 300i Magnetic Cell Selection System machine used in this investigational study. The Isolex 300i Magnetic Cell Selection System, which is approved for use in oncology patients, purifies the subject's stem cells to provide only the CD34 stem cells. Dr. Losordo is also a paid consultant to Baxter.

For more information: www.fcvri.northwestern.edu/index.html

Related Content

New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral| July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Artery Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies| June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies| May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral| April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies| April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Overlay Init